Nuclear oculomotor paralysis

Summary

Nuclear oculomotor paralysis (MONDO:0015083) is a disease (an umbrella term covering 6 Mondo subtypes). A subtype of oculomotor nerve paralysis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 6 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nuclear oculomotor paralysis
Mondo ID	MONDO:0015083
Orphanet	100932
Is cancer (heuristic)	no

Disease family

This is a subtype of oculomotor nerve paralysis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › cranial nerve neuropathy › cranial nerve palsy › oculomotor nerve paralysis › nuclear oculomotor paralysis

Related subtypes (4): partial third-nerve palsy, total third-nerve palsy, total internal ophthalmoplegia, supranuclear oculomotor palsy

Subtypes (6): Duane retraction syndrome, familial congenital palsy of trochlear nerve, Mobius syndrome, congenital oculomotor nerve palsy, congenital abducens nerve palsy, Tolosa-Hunt syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.